MedPath

Labatec Pharma SA

Labatec Pharma SA logo
🇨🇭Switzerland
Ownership
Private
Established
1957-01-01
Employees
101
Market Cap
-
Website
http://www.labatecpharma.com

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Conditions
Osteoporosis, Postmenopausal
Interventions
First Posted Date
2018-02-15
Last Posted Date
2020-12-03
Lead Sponsor
Labatec Pharma SA
Target Recruit Count
80
Registration Number
NCT03435094
Locations
🇨🇭

Endokrinologische Praxis & Labor, Basel, BS, Switzerland

🇨🇭

Hôpital Universitaire de Genève, Service des maladies osseuses, Genève, GE, Switzerland

© Copyright 2025. All Rights Reserved by MedPath